Corcept Therapeutics (HAM:HTD) Cyclically Adjusted Revenue per Share: €3.18 (As of Mar. 2026)


HAM:HTD Corcept Therapeutics Inc HAM:HTD
85 GF Score
Price €78.94
GF Value €54.59
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Cyclically Adjusted Revenue per Share?

Corcept Therapeutics HAM:HTD +1.60% 85 Cyclically Adjusted Revenue per Share is €3.18 as of Mar. 2026. GuruFocus rates HAM:HTD with a GF Score™ of 85/100 and a GF Value™ of €54.59. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Corcept Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was €1.366. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.18 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Corcept Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 22.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 25.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 25.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 34.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Corcept Therapeutics was 77.60% per year. The lowest was 23.80% per year. And the median was 36.70% per year.

As of today (2026-07-04), Corcept Therapeutics's current stock price is €78.94. Corcept Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €3.18. Corcept Therapeutics's Cyclically Adjusted PS Ratio of today is 24.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Corcept Therapeutics was 53.40. The lowest was 8.86. And the median was 16.18.


Corcept Therapeutics  (HAM:HTD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Corcept Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=78.94/3.18
=24.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Corcept Therapeutics was 53.40. The lowest was 8.86. And the median was 16.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Corcept Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Corcept Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Cyclically Adjusted Revenue per Share Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 7.07

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 7.07 3.18

HAM:HTD vs PRAX, IBRX, NUVL: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Corcept Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Cyclically Adjusted PS Ratio falls into.


HAM:HTD
85GF Score
Corcept Therapeutics Inc HAM:HTD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corcept Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.366/330.2130*330.2130
=1.366

Current CPI (Mar. 2026) = 330.2130.

Corcept Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.152 241.018 0.208
201609 0.166 241.428 0.227
201612 0.190 241.432 0.260
201703 0.213 243.801 0.288
201706 0.257 244.955 0.346
201709 0.286 246.819 0.383
201712 0.352 246.524 0.471
201803 0.366 249.554 0.484
201806 0.418 251.989 0.548
201809 0.438 252.439 0.573
201812 0.469 251.233 0.616
201903 0.463 254.202 0.601
201906 0.525 256.143 0.677
201909 0.608 256.759 0.782
201912 0.644 256.974 0.828
202003 0.690 258.115 0.883
202006 0.638 257.797 0.817
202009 0.589 260.280 0.747
202012 0.556 260.474 0.705
202103 0.515 264.877 0.642
202106 0.600 271.696 0.729
202109 0.653 274.310 0.786
202112 0.715 278.802 0.847
202203 0.739 287.504 0.849
202206 0.848 296.311 0.945
202209 0.881 296.808 0.980
202212 0.836 296.797 0.930
202303 0.855 301.836 0.935
202306 0.991 305.109 1.073
202309 1.042 307.789 1.118
202312 1.121 306.746 1.207
202403 1.229 312.332 1.299
202406 1.368 314.175 1.438
202409 1.446 315.301 1.514
202412 1.457 315.605 1.524
202503 1.214 319.799 1.254
202506 1.399 322.561 1.432
202509 1.481 324.800 1.506
202512 1.438 324.054 1.465
202603 1.366 330.213 1.366

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.18 mean?
Corcept Therapeutics (HAM:HTD) has a Cyclically Adjusted Revenue per Share of €3.18 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Cyclically Adjusted Revenue per Share too high?
Corcept Therapeutics' current Cyclically Adjusted Revenue per Share is €3.18. Overall, Corcept Therapeutics has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Cyclically Adjusted Revenue per Share compare to PRAX and IBRX?
Corcept Therapeutics' Cyclically Adjusted Revenue per Share of €3.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Cyclically Adjusted Revenue per Share is €3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Cyclically Adjusted Revenue per Share of €3.18. The stock's GF Value™ is €54.59, compared to a current price of €78.94 — trading 44.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.18. Corcept Therapeutics' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Cyclically Adjusted Revenue per Share is €3.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €78.94 is trading 44.6% above its estimated GF Value™ of €54.59.

Key valuation signals for HAM:HTD:

  • Cyclically Adjusted Revenue per Share: €3.18
  • GF Value™: €54.59 vs. price of €78.94 (44.6% above fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score

Get the complete analysis for HAM:HTD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.94
Price
€54.59
GF Value